Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
3.520
-0.100 (-2.76%)
Nov 12, 2024, 4:00 PM EST - Market closed

Company Description

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.

The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.

Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Mural Oncology plc
Mural Oncology logo
Country Ireland
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 117
CEO Caroline Loew

Contact Details

Address:
10 Earlsfort Terrace
Dublin, D02 T380
Ireland
Phone 353 1 905 8020
Website muraloncology.com

Stock Details

Ticker Symbol MURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001971543
ISIN Number IE000LK2BOB4
SIC Code 2834

Key Executives

Name Position
Caroline J. Loew Ph.D. President, Chief Executive Officer and Director
Adam D. Cutler B.A. Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Vicki L. Goodman M.D. Chief Medical Officer
Maiken Keson-Brookes Chief Legal Officer
Justin Levine Head of Human Resources and Vice President of Human Resources

Latest SEC Filings

Date Type Title
Nov 8, 2024 144 Filing
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 1, 2024 144 Filing
Sep 26, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Aug 13, 2024 SCHEDULE 13G Filing
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Aug 5, 2024 8-K Current Report